As described before, synaptic dysfunction is a common pathogenic event in AD. Synaptic dysfunction occurs early in AD, most likely in the pre-symptomatic stages. Moreover, synaptic dysfunction is, so far, the best correlate of cognitive decline. Given that synapses have a great plasticity to be restored, it is plausible that improved synaptic function could lead to improved cognition. Therefor the aim of the SyDAD project is to get a better understanding of both synaptic function and dysfunction in AD, and thereby identify targets for pharmaceutical interventions that could ultimately restore synaptic function in AD.